Greenwich Net Tangible Assets vs Total Current Liabilities Analysis

GLSI Stock

USD 11.57 0.08 0.70%

Greenwich Lifesciences financial indicator trend analysis is much more than just examining Greenwich Lifesciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Greenwich Lifesciences is a good investment. Please check the relationship between Greenwich Lifesciences Net Tangible Assets and its Total Current Liabilities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.

Net Tangible Assets vs Total Current Liabilities

Net Tangible Assets vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Greenwich Lifesciences Net Tangible Assets account and Total Current Liabilities. At this time, the significance of the direction appears to have very week relationship.

The correlation between Greenwich Lifesciences' Net Tangible Assets and Total Current Liabilities is 0.21. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Greenwich Lifesciences, assuming nothing else is changed. The correlation between historical values of Greenwich Lifesciences' Net Tangible Assets and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Greenwich Lifesciences are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Net Tangible Assets i.e., Greenwich Lifesciences' Net Tangible Assets and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.21

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Total Current Liabilities

Total Current Liabilities is an item on Greenwich Lifesciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Greenwich Lifesciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Greenwich Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Greenwich Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.As of now, Greenwich Lifesciences' Selling General Administrative is increasing as compared to previous years. The Greenwich Lifesciences' current Issuance Of Capital Stock is estimated to increase to about 5.1 M, while Enterprise Value Over EBITDA is projected to decrease to (9.45).

	2024	2025 (projected)
Total Operating Expenses	16.0M	16.8M
Cost Of Revenue	4.2K	4.0K

Total Operating Expenses Cost Of Revenue

Greenwich Lifesciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Liab	Net Tangible Assets	Current Deferred Revenue	Common Stock Total Equity	Net Invested Capital	Capital Stock	Net Working Capital	Intangible Assets	Short Term Debt
Total Assets		-0.06	-0.04	0.97	-1.0	-0.22	-0.03	1.0	-0.44	1.0	0.57	-0.63	0.72	-0.68	1.0	0.72	-0.64	0.05	0.69	0.64	0.34	0.96	0.68	1.0	-0.4	-0.75
Other Current Liab	-0.06		0.65	-0.08	0.06	0.31	0.11	-0.06	0.3	-0.06	-0.35	0.11	-0.24	0.11	-0.06	-0.15	0.06	0.11	-0.25	-0.06	-0.44	-0.08	-0.12	-0.08	0.35	0.31
Total Current Liabilities	-0.04	0.65		0.05	0.04	-0.35	0.74	-0.04	-0.28	-0.04	0.14	-0.32	0.25	-0.26	-0.04	0.27	-0.35	-0.41	0.21	0.35	0.19	0.07	0.31	-0.08	-0.25	-0.12
Total Stockholder Equity	0.97	-0.08	0.05		-0.97	-0.4	0.12	0.97	-0.61	0.97	0.69	-0.8	0.84	-0.83	0.97	0.86	-0.8	-0.07	0.82	0.8	0.53	1.0	0.83	0.97	-0.57	-0.85
Net Debt	-1.0	0.06	0.04	-0.97		0.23	0.02	-1.0	0.45	-1.0	-0.58	0.64	-0.72	0.68	-1.0	-0.72	0.65	-0.04	-0.7	-0.65	-0.35	-0.97	-0.69	-1.0	0.4	0.75
Retained Earnings	-0.22	0.31	-0.35	-0.4	0.23		-0.76	-0.22	0.96	-0.22	-0.89	0.77	-0.81	0.7	-0.22	-0.76	0.75	0.78	-0.85	-0.75	-0.89	-0.42	-0.77	-0.2	0.97	0.78
Accounts Payable	-0.03	0.11	0.74	0.12	0.02	-0.76		-0.03	-0.65	-0.03	0.6	-0.52	0.46	-0.41	-0.03	0.44	-0.52	-0.89	0.52	0.52	0.62	0.14	0.5	-0.07	-0.66	-0.37
Cash	1.0	-0.06	-0.04	0.97	-1.0	-0.22	-0.03		-0.44	1.0	0.57	-0.63	0.72	-0.68	1.0	0.72	-0.64	0.05	0.69	0.64	0.34	0.96	0.68	1.0	-0.4	-0.75
Non Current Assets Total	-0.44	0.3	-0.28	-0.61	0.45	0.96	-0.65	-0.44		-0.44	-0.95	0.9	-0.92	0.85	-0.44	-0.9	0.89	0.65	-0.95	-0.89	-0.93	-0.64	-0.91	-0.43	0.99	0.9
Cash And Short Term Investments	1.0	-0.06	-0.04	0.97	-1.0	-0.22	-0.03	1.0	-0.44		0.57	-0.63	0.72	-0.68	1.0	0.72	-0.64	0.05	0.69	0.64	0.34	0.96	0.68	1.0	-0.4	-0.75
Common Stock Shares Outstanding	0.57	-0.35	0.14	0.69	-0.58	-0.89	0.6	0.57	-0.95	0.57		-0.84	0.89	-0.79	0.57	0.85	-0.83	-0.69	0.96	0.83	0.85	0.71	0.86	0.56	-0.94	-0.9
Non Current Liabilities Total	-0.63	0.11	-0.32	-0.8	0.64	0.77	-0.52	-0.63	0.9	-0.63	-0.84		-0.93	0.99	-0.63	-0.98	0.99	0.42	-0.93	-0.99	-0.87	-0.82	-0.99	-0.62	0.87	0.88
Other Stockholder Equity	0.72	-0.24	0.25	0.84	-0.72	-0.81	0.46	0.72	-0.92	0.72	0.89	-0.93		-0.92	0.72	0.97	-0.92	-0.4	0.98	0.92	0.83	0.85	0.96	0.71	-0.9	-0.99
Total Liab	-0.68	0.11	-0.26	-0.83	0.68	0.7	-0.41	-0.68	0.85	-0.68	-0.79	0.99	-0.92		-0.68	-0.98	0.99	0.3	-0.91	-0.99	-0.83	-0.85	-0.99	-0.67	0.82	0.88
Total Current Assets	1.0	-0.06	-0.04	0.97	-1.0	-0.22	-0.03	1.0	-0.44	1.0	0.57	-0.63	0.72	-0.68		0.72	-0.64	0.05	0.69	0.64	0.34	0.96	0.68	1.0	-0.4	-0.75
Common Stock	0.72	-0.15	0.27	0.86	-0.72	-0.76	0.44	0.72	-0.9	0.72	0.85	-0.98	0.97	-0.98	0.72		-0.98	-0.35	0.96	0.98	0.84	0.87	1.0	0.7	-0.87	-0.94
Short Long Term Debt Total	-0.64	0.06	-0.35	-0.8	0.65	0.75	-0.52	-0.64	0.89	-0.64	-0.83	0.99	-0.92	0.99	-0.64	-0.98		0.4	-0.92	-1.0	-0.85	-0.82	-0.99	-0.63	0.85	0.87
Other Liab	0.05	0.11	-0.41	-0.07	-0.04	0.78	-0.89	0.05	0.65	0.05	-0.69	0.42	-0.4	0.3	0.05	-0.35	0.4		-0.52	-0.4	-0.58	-0.09	-0.4	0.08	0.68	0.37
Net Tangible Assets	0.69	-0.25	0.21	0.82	-0.7	-0.85	0.52	0.69	-0.95	0.69	0.96	-0.93	0.98	-0.91	0.69	0.96	-0.92	-0.52		0.92	0.85	0.83	0.96	0.68	-0.93	-0.98
Current Deferred Revenue	0.64	-0.06	0.35	0.8	-0.65	-0.75	0.52	0.64	-0.89	0.64	0.83	-0.99	0.92	-0.99	0.64	0.98	-1.0	-0.4	0.92		0.85	0.82	0.99	0.63	-0.85	-0.87
Common Stock Total Equity	0.34	-0.44	0.19	0.53	-0.35	-0.89	0.62	0.34	-0.93	0.34	0.85	-0.87	0.83	-0.83	0.34	0.84	-0.85	-0.58	0.85	0.85		0.55	0.86	0.33	-0.93	-0.78
Net Invested Capital	0.96	-0.08	0.07	1.0	-0.97	-0.42	0.14	0.96	-0.64	0.96	0.71	-0.82	0.85	-0.85	0.96	0.87	-0.82	-0.09	0.83	0.82	0.55		0.85	0.96	-0.59	-0.86
Capital Stock	0.68	-0.12	0.31	0.83	-0.69	-0.77	0.5	0.68	-0.91	0.68	0.86	-0.99	0.96	-0.99	0.68	1.0	-0.99	-0.4	0.96	0.99	0.86	0.85		0.67	-0.87	-0.92
Net Working Capital	1.0	-0.08	-0.08	0.97	-1.0	-0.2	-0.07	1.0	-0.43	1.0	0.56	-0.62	0.71	-0.67	1.0	0.7	-0.63	0.08	0.68	0.63	0.33	0.96	0.67		-0.38	-0.74
Intangible Assets	-0.4	0.35	-0.25	-0.57	0.4	0.97	-0.66	-0.4	0.99	-0.4	-0.94	0.87	-0.9	0.82	-0.4	-0.87	0.85	0.68	-0.93	-0.85	-0.93	-0.59	-0.87	-0.38		0.88
Short Term Debt	-0.75	0.31	-0.12	-0.85	0.75	0.78	-0.37	-0.75	0.9	-0.75	-0.9	0.88	-0.99	0.88	-0.75	-0.94	0.87	0.37	-0.98	-0.87	-0.78	-0.86	-0.92	-0.74	0.88

Click cells to compare fundamentals

Greenwich Lifesciences Account Relationship Matchups

Greenwich Lifesciences fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	28.7M	27.2M	13.5M	7.0M	4.1M	3.9M
Other Current Liab	770.3K	164.3K	42.1K	258.9K	382.2K	320.7K
Total Current Liabilities	1.0M	385.2K	262.9K	294.4K	1.6M	854.0K
Total Stockholder Equity	27.6M	26.8M	13.2M	6.7M	2.5M	2.4M
Net Debt	(28.7M)	(27.2M)	(13.5M)	(7.0M)	(4.1M)	(4.3M)
Retained Earnings	(29.1M)	(33.6M)	(41.5M)	(50.4M)	(66.2M)	(62.8M)
Accounts Payable	635.2K	275.2K	220.8K	35.5K	1.2M	1.2M
Cash	28.7M	27.2M	13.5M	7.0M	4.1M	3.9M
Non Current Assets Total	16.2K	12.6K	9.0K	5.4K	1.8K	1.7K
Cash And Short Term Investments	28.7M	27.2M	13.5M	7.0M	4.1M	3.9M
Common Stock Shares Outstanding	12.7M	12.9M	12.9M	12.8M	13.0M	13.7M
Liabilities And Stockholders Equity	28.7M	27.2M	13.5M	7.0M	4.1M	3.9M
Other Stockholder Equity	56.7M	60.5M	54.7M	57.1M	68.7M	48.2M
Total Liab	1.0M	385.2K	262.9K	294.4K	1.6M	2.4M
Total Current Assets	28.7M	27.2M	13.5M	7.0M	4.1M	3.9M
Common Stock	8.5K	12.7K	13.1K	12.8K	13.2K	10.2K
Net Invested Capital	27.6M	26.8M	13.2M	6.7M	2.5M	2.4M
Capital Stock	10.4K	12.7K	13.1K	12.8K	13.2K	12.2K
Net Working Capital	27.6M	26.8M	13.2M	6.7M	2.5M	2.4M
Intangible Assets	16.2K	12.6K	9.0K	5.4K	1.8K	1.7K

Currently Active Assets on Macroaxis

USOI	Credit Suisse X Links
ULTY	Tidal Trust II
CONY	YieldMax N Option
BCAT	BlackRock Capital Allocation
PDI	Pimco Dynamic Income

When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:

How To Invest In Greenwich

Details

Is Greenwich Stock a good investment?

Details

What is Greenwich Lifesciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.27)

Return On Assets

(2.54)

Return On Equity

(5.15)

The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Greenwich Net Tangible Assets vs Total Current Liabilities Analysis

Net Tangible Assets vs Total Current Liabilities

Net Tangible Assets vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Total Current Liabilities

Greenwich Lifesciences fundamental ratios Correlations

Greenwich Lifesciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Greenwich Lifesciences fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash

Current Deferred Revenue	- 1.0	Short Long Term Debt Total
Net Working Capital	- 1.0	Net Debt
Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets